Landos Biopharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-06-01
- Employees
- 19
- Market Cap
- -
Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis
Phase 1
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: NX-13 250mg IRDrug: NX-13 500mg IRDrug: NX-13 500mg MRDrug: Placebo
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Landos Biopharma Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04862741
- Locations
- 🇺🇸
Avant Research Associates LLC, Huntsville, Alabama, United States
🇺🇸Om Research LLC, Lancaster, California, United States
🇺🇸Allameh Medical Corporation, Mission Viejo, California, United States
Safety, Tolerability and Pharmacokinetics of Oral NX-13 in Healthy Adults Male and Female Volunteers
Phase 1
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: NX-13 250 mgDrug: Placebo
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Landos Biopharma Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT04458805
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Australia
News
No news found